Overview
CARA Medical builds software that helps doctors visualize the heart's electrical conduction system without surgery. Its tools use a patient’s CT angiography to create a personalized 3D map of the conduction pathways and provide navigation during procedures. The CARA Metis software generates a pre-procedure 3D overlay of the conduction system to aid planning, while CARA Atlas offers interactive, real-time 3D guidance during interventions. This setup supports conduction system pacing and structural heart procedures such as TAVR, TMVR, and TTVR. Compared with others, CARA Medical emphasizes patient-specific, non-invasive visualization derived from existing imaging to inform planning and execution, backed by a leadership team with deep experience in cardiac imaging and medical devices. The company’s goal is to reduce procedural risks and improve the precision of cardiac device placement, ultimately improving outcomes for patients undergoing complex heart procedures.
Work here?Claim your company
Simplify's take
What believers are saying
- CARA reported ongoing multicenter TAVR and CSP studies in November 2026.
- Publications with Cleveland Clinic, Mayo, and European centers validate clinical relevance.
- FDA clearance plus breakthrough status lowers purchasing friction for early adopters.
What critics are saying
- CARA still lacks disclosed U.S. commercial traction after February 2026 clearance.
- Cydar EV already owns the same fluoroscopic-overlay workflow CARA uses.
- If multicenter studies miss outcomes, hospitals will treat CARA as optional visualization software.
What makes CARA Medical unique
- CARA System won FDA 510(k) clearance on February 20, 2026.
- It converts CTA scans into patient-specific conduction maps for TAVR and CSP.
- Shlomo Ben-Haim brings CARTO credibility, patents, and physician-adoption relationships.
Help us improve and share your feedback! Did you find this helpful?